Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin liposomal non-pegylated
- Development stage
- Phase 3
- Lead developer
- CHEPLAPHARM
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Doxorubicin liposomal non-pegylated (commonly marketed under the brand name Myocet) is a non-pegylated liposomal formulation of the anthracycline chemotherapy agent doxorubicin hydrochloride. It is designed to optimize the therapeutic index of doxorubicin by encapsulating the drug within liposomes, which alters its pharmacokinetics and tissue distribution. This formulation significantly reduces the risk of cumulative, dose-dependent cardiotoxicity (such as congestive heart failure) compared to conventional doxorubicin, while maintaining comparable antitumor efficacy. It is approved in Europe and Canada, in combination with cyclophosphamide, for the first-line treatment of metastatic breast cancer in adult women. The asset was originally developed by The Liposome Company (later acquired by Elan), with subsequent development and commercialization rights held by Cephalon, Teva, and more recently acquired by Cheplapharm in Europe, with Mediolanum Farmaceutici (via its subsidiary Istituto Gentili) handling commercialization in Italy.
- Brand names
- EvacetMyocetMyocet liposomal
- Other names
- doxorubicin citrate liposomedoxorubicin hydrochloride liposomaldoxorubicin liposomal non-pegylatedliposome-encapsulated doxorubicinnon-pegylated liposomal doxorubicinnon-pegylated liposomal doxorubicin hydrochloride
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)Pol III (Dna-directed RNA polymerase III)
Beyond the preview
Go deeper on doxorubicin liposomal non-pegylated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin liposomal non-pegylated.